Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14578314 | 0.88 | PRMT3 (0.40) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL12901248 | 0.85 | PRMT3 (0.38) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL18467909 | 0.79 | PIK3CD (0.43) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL25923890 | 0.78 | PRMT3 (0.33) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL24764770 | 0.77 | — | — | |
| SCHEMBL15120327 | 0.76 | PRMT3 (0.32) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL17366451 | 0.76 | PRMT3 (0.32) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL14578306 | 0.76 | PRMT3 (0.32) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL13589014 | 0.75 | — | — | |
| SCHEMBL15919032 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110045027-A1 | Adjuvant | GLAXO GROUP LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045027-A1 | Adjuvant | TLR3, TLR9, TLR7 | PRMT3 2680/4885CARM1 3515/4885PRMT6 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.